Diligence memo · auto-generated · as of July 2, 2026
S1P Therapeutics Inc.
S1P Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
S1P Therapeutics Inc. operates in Pharmaceuticals, based in BLACKSBURG.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
S1P Therapeutics Inc. has raised $2.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2023-05-31.
Most recent recorded round closed around 2023-05-31.
Valuation (modeled)modeled
Provath models S1P Therapeutics Inc. at approximately $17M (range $1.5M–$60M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.75× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.1 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 28% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 25% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.